摘要
筛选可协同增效头孢噻呋钠抗耐甲氧西林金黄色葡萄球菌(MRSA)的抑制剂。从多种黄酮类中药单体成分和海洋生物材料中筛选出可以增强头孢噻呋钠对MRSA敏感性的活性成分;以棋盘稀释法测定中药单体和头孢噻呋钠的体外协同抗MRSA作用,并计算其分级抑菌浓度指数(FICI)。原花青素、二氢杨梅素和矢车菊素-3-O-葡萄糖苷3种中药单体与头孢噻呋钠联合应用对ATCC 33591的FIC分别为0.375、0.375、0.2359。海洋生物材料对ATCC 33591的抗菌效果不明显。MIC、MBC测定验证了原花青素可增强MRSA对头孢噻呋钠的敏感性,且原花青素与头孢噻呋钠对临床MRSA菌株均呈现明显的协同增效作用,对PRSA菌株均呈现相加抗菌作用。矢车菊素-3-O-葡萄糖苷、二氢杨梅素、原花青素、巴西苏木素、血竭素高氯酸盐对ATCC 33591具有较好的抑菌作用;原花青素、二氢杨梅素和矢车菊素-3-O-葡萄糖苷这3种中药单体与头孢噻呋钠联合应用对ATCC 33591有明显的协同增效作用,具有成为MRSA耐药菌抑制剂的潜力。
The aim of this study was to screen inhibitors that can synergize ceftiofur sodium against MRSA.The active components that could increase the sensitivity of ceftiofur sodium against MRSA were screened out from a variety of flavonoids of Chinese medicine monomers and materials of marine organisms;The synergistic effect between Chinese medicine monomers and ceftiofur sodium in vitro against MRSA was determined by microdilution method,and its FIC index(fractional inhibitory concentration index,FICI)was calculated.Procyanidins,dihydromyricetin and cyanidin-3-O-glucoside,the three Chinese medicine monomers combined with ceftiofur sodium showed FIC indexes as 0.375,0.375,and 0.2359 against ATCC 33591,respectively.The materials of marine organisms had no obvious antibacterial effect against ATCC 33591.The results of MIC and MBC determinations verified that proanthocyanidin increased the sensitivity of MRSA to ceftiofur sodium,and both procyanidin and ceftiofur sodium had a significant synergistic effect against clinical MRSA strains and an additive antibacterial effect against PRSA strains.Cyanidin-3-O-glucoside,proanthocyanidin,dihydromyricetin,Brazil haematoxylin,and draconsin perchlorate showed good antibacterial effects against MRSA ATCC 33591.Proanthocyanidins,dihydromyricetin and cyanidin-3-O-glucoside,the three Chinese medicine monomers,combined with ceftiofur sodium showed a significant synergistic effect against MRSA ATCC 33591,which showed their potential to be developed as inhibitors of MRSA resistant bacteria.
作者
郝红侠
任海燕
胡龙飞
刘旭东
赵红琼
郝智慧
HAO Hong-xia;REN Hai-yan;HU Long-fei;LIU Xu-dong;ZHAO Hong-qiong;HAO Zhi-hui(College of Veterinary Medicine,Xinjiang Agricultural University,Urumuqi,Xinjiang,830052,China;Chinese Veterinary Medicine Innovation Center,China Agricultural University,Beijing,100193,China;Agricultural Biopharmaceutical Laboratory of Qingdao Agricultural University,Shandong,Qingdao,266109,China)
出处
《动物医学进展》
北大核心
2022年第3期63-67,共5页
Progress In Veterinary Medicine
基金
“外专双百计划”团队项目(WAT2017010)
中国农业大学“人才培育发展支持计划”项目。
